FDA Approves THALOMID — Celgene Corporation

Celgene Corporation rallied on July 16, 1998, following the FDA's approval of its oral Thalomid (thalidomide) therapy, marking a pivotal moment for the drug maker that market analysts projected would become a cornerstone asset in the treatment of multiple myeloma.